Brief: Lidds Announces Preliminary Results From Phase IIb Liproca Depot Dose-finding Study

Lidds AB

24/09/2019 07:40

Sept 24 (Reuters) - Lidds AB  LIDDS.ST :
    * REG-PRELIMINARY RESULTS FROM PHASE IIB LIPROCA® DEPOT
DOSE-FINDING STUDY SHOW A STRONG MAXIMUM PSA DECREASE AND
SUSTAINED PSA REDUCTION EFFECT
    * LIDDS - PSA REDUCTION FOR PART II PATIENTS WAS IN LINE
WITH
EXPECTED PATTERN FOR LIPROCA DEPOT'S SUSTAINED RELEASE AND
MAXIMUM PSA REDUCTION (PSA NADIR) OCCURRED DURING MONTHS 2-4
    * PATIENTS IN PART II SHOWED A STRONG PSA DECREASE AND A
CONTINUED
PSA REDUCTION AT MONTH 5 AS WELL AS OVER FULL STUDY PERIOD OF
SIX MONTHS, CONFIRMING NANOZOLID® TECHNOLOGY'S SUSTAINED RELEASE
PROFILE
    * POSITIVE PRELIMINARY RESULTS SHOW LIPROCA® DEPOT'S ABILITY
TO
REDUCE PSA LEVELS OVER A PERIOD OF SIX MONTHS, PROVING
NANOZOLID® TECHNOLOGY'S SUITABILITY FOR LOCAL CANCER TREATMENT
    * STUDY ALSO CONFIRMS TECHNOLOGY'S FAVORABLE TOXICITY AND
TOLERABILITY PROFILE
    * LIDDS - LIPROCA DEPOT WAS WELL TOLERATED WITHOUT HORMONAL
SIDE
EFFECTS ASSOCIATED WITH ANTI-ANDROGEN THERAPIES
    * LIDDS - MAJORITY OF PATIENTS IN STUDY WERE POSITIVE TO
RECEIVING
A SECOND INJECTION

Source text for Eikon:  ID:nGNE3PJG8X 
Further company coverage:  LIDDS.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com;))